Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranos
- PDF / 6,929,360 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 6 Downloads / 129 Views
RESEARCH ARTICLE
Open Access
Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine Erkhem-Ochir Bilguun1,2†, Kyoichi Kaira3†, Reika Kawabata-Iwakawa4†, Susumu Rokudai2, Kimihiro Shimizu1,5, Takehiko Yokobori4, Tetsunari Oyama6, Ken Shirabe1 and Masahiko Nishiyama7,8*
Abstract Background: Lung squamous cell carcinoma (LSCC) remains a challenging disease to treat, and further improvements in prognosis are dependent upon the identification of LSCC-specific therapeutic biomarkers and/or targets. We previously found that Syntaxin Binding Protein 4 (STXBP4) plays a crucial role in lesion growth and, therefore, clinical outcomes in LSCC patients through regulation of tumor protein p63 (TP63) ubiquitination. Methods: To clarify the impact of STXBP4 and TP63 for LSCC therapeutics, we assessed relevance of these proteins to outcome of 144 LSCC patients and examined whether its action pathway is distinct from those of currently used drugs in in vitro experiments including RNA-seq analysis through comparison with the other putative exploratory targets and/or markers. (Continued on next page)
* Correspondence: [email protected] † Erkhem-Ochir Bilguun, Kyoichi Kaira and Reika Kawabata-Iwakawa contributed equally to this work. 7 Gunma University, 3-9-22 Showa-machi, Maebashi, Gunma 371-8511, Japan 8 Higashi Sapporo Hospital, 7-35, 3-3 Higashi-Sapporo, Shiroishi-ku, Sapporo 003-8585, Japan Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Bilguun et al. BMC Cancer
(2020) 20:935
Page 2 of 14
(Continued from previous page)
Results: Kaplan–Meier analysis revealed that, along with vascular endothelial growth factor receptor 2 (VEGFR2), STXBP4 expression signified a worse prognosis in LSCC patients, both in terms of overall survival (OS, p = 0.002) and disease-free survival (DFS, p = 0.041). These prognostic impacts of STXBP4 were co
Data Loading...
